Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412041 | 1.00 | PDE4B (0.49) | PDE4BHDAC1HDAC2CHEK2GPR119 | |
| SCHEMBL2409128 | 1.00 | PDE4B (0.49) | PDE4BHDAC1HDAC2CHEK2GPR119 | |
| SCHEMBL2409365 | 0.94 | HDAC1 (0.52) | PDE4BHDAC1HDAC2GPR119KDM1A | |
| SCHEMBL2409370 | 0.94 | HDAC1 (0.52) | PDE4BHDAC1HDAC2GPR119KDM1A | |
| SCHEMBL2406416 | 0.88 | PDE4B (0.48) | PDE4BHDAC1HDAC2CHEK2GPR119 | |
| SCHEMBL2406418 | 0.88 | PDE4B (0.48) | PDE4BHDAC1HDAC2CHEK2GPR119 | |
| SCHEMBL6113438 | 0.87 | GPR119 (0.55) | PDE4BHDAC1HDAC2GPR119KDM1A | |
| SCHEMBL15057700 | 0.86 | PDE4B (0.51) | PDE4BCHEK2GPR119SCN9AUSP30 | |
| SCHEMBL15057701 | 0.86 | PDE4B (0.51) | PDE4BCHEK2GPR119SCN9AUSP30 | |
| SCHEMBL15058691 | 0.85 | PDE4B (0.48) | PDE4BCHEK2GPR119SCN9AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539344-B1 | HALOGEN OR CYANO SUBSTITUTED THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2539344-B1 | HALOGEN OR CYANO SUBSTITUTED THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2539346-B1 | 4-[HETEROCYCLOALKYLOXY(HETERO)ARYLAMINO] THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20130065914-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065914-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065914-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| EP-2539344-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011104338-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104338-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, TNK2, CMPK1 | PDE4B 812/4885HDAC1 3177/4885HDAC2 1706/4885 |
| US-20130065914-A1 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | NEK2, CMPK1, NEK9 | PDE4B 1182/4885HDAC1 1893/4885HDAC2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.